edotreotide has been researched along with Recrudescence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balogova, S; Huchet, V; Kerrou, K; Michaud, L; Montravers, F; Nataf, V; Talbot, JN | 1 |
| Bodei, L; Capanna, R; De Braud, F; De Pas, T; Paganelli, G; Pelosi, G; Villa, G | 1 |
1 review(s) available for edotreotide and Recrudescence
| Article | Year |
|---|---|
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Recurrence; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2013 |
1 other study(ies) available for edotreotide and Recrudescence
| Article | Year |
|---|---|
Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group.
Topics: Adult; Female; Fibromatosis, Aggressive; Humans; Male; Octreotide; Radiopharmaceuticals; Radiotherapy, Adjuvant; Receptors, Peptide; Recurrence; Retrospective Studies | 2003 |